Trials / Completed
CompletedNCT02732210
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 935 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
Detailed description
The study was a multi-center, single-arm, prospective, non-interventional observational study in postmenopausal women with osteoporosis who had been treated with Prolia® for osteoporosis in routine clinical practice.
Conditions
Timeline
- Start date
- 2011-07-06
- Primary completion
- 2014-04-07
- Completion
- 2014-04-14
- First posted
- 2016-04-08
- Last updated
- 2022-11-29
- Results posted
- 2016-12-14
Locations
89 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02732210. Inclusion in this directory is not an endorsement.